Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Down 85.9% in December

Sutro Biopharma, Inc. (NASDAQ:STRO) was the target of a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 560,264 shares, a decline of 85.9% from the November 30th total of 3,977,435 shares. Based on an average daily volume of 139,822 shares, the short-interest ratio is presently 4.0 days. Approximately 7.0% of the company’s shares are sold short. Approximately 7.0% of the company’s shares are sold short. Based on an average daily volume of 139,822 shares, the short-interest ratio is presently 4.0 days.

Sutro Biopharma Stock Performance

NASDAQ STRO traded up $0.25 during trading on Wednesday, hitting $10.63. The stock had a trading volume of 40,237 shares, compared to its average volume of 116,353. Sutro Biopharma has a 12 month low of $5.23 and a 12 month high of $21.50. The company’s 50-day moving average price is $9.48 and its two-hundred day moving average price is $8.79. The company has a market capitalization of $90.42 million, a PE ratio of -0.41 and a beta of 1.61.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.25). The business had revenue of $9.69 million during the quarter, compared to analyst estimates of $10.14 million. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. As a group, equities analysts anticipate that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

STRO has been the subject of a number of recent analyst reports. Wedbush reaffirmed a “neutral” rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday. Wall Street Zen downgraded shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. HC Wainwright lifted their price target on shares of Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research report on Monday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sutro Biopharma in a research note on Wednesday, December 17th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $33.60.

Insider Buying and Selling

In related news, Director Connie Matsui acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The stock was acquired at an average price of $8.00 per share, for a total transaction of $40,000.00. Following the completion of the acquisition, the director owned 5,000 shares of the company’s stock, valued at $40,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders bought a total of 11,175 shares of company stock valued at $89,598 in the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Sutro Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. CWM LLC raised its stake in Sutro Biopharma by 73.2% in the second quarter. CWM LLC now owns 56,657 shares of the company’s stock valued at $40,000 after buying an additional 23,941 shares during the period. Vestal Point Capital LP increased its holdings in shares of Sutro Biopharma by 1.2% during the 1st quarter. Vestal Point Capital LP now owns 2,600,000 shares of the company’s stock worth $1,692,000 after acquiring an additional 30,000 shares during the last quarter. Bridgeway Capital Management LLC increased its holdings in shares of Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after acquiring an additional 30,000 shares during the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in Sutro Biopharma in the 2nd quarter valued at $27,000. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in Sutro Biopharma by 174.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock valued at $43,000 after purchasing an additional 38,561 shares during the last quarter. 96.99% of the stock is owned by institutional investors.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.